Detalhe da pesquisa
1.
Bayesian borrowing from historical control data in a vaccine efficacy trial.
Pharm Stat
; 22(5): 815-835, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37226586
2.
Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials.
J Infect Dis
; 225(2): 332-340, 2022 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34174082
3.
Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America.
J Infect Dis
; 217(5): 742-753, 2018 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29194547
4.
Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America.
J Infect Dis
; 214(7): 994-1000, 2016 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27418050
5.
Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries.
Trans R Soc Trop Med Hyg
; 115(7): 750-763, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33369671
6.
Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America.
PLoS One
; 15(6): e0234236, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32542024
7.
Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.
Am J Trop Med Hyg
; 101(1): 164-179, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31115304
8.
Age-specific prevalence of dengue antibodies in Bangkok infants and children.
Pediatr Infect Dis J
; 27(5): 461-3, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18360303
9.
Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease.
PLoS One
; 13(12): e0207878, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30543657
10.
Combined typhoid fever and hepatitis A vaccine: comparison of immunogenicity and safety to concomitant monovalent vaccine over 3 years.
J Travel Med
; 12(6): 319-26, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-16343383
11.
Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study.
Vaccine
; 33(39): 5127-34, 2015 Sep 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-26279339
12.
Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children.
Pediatr Infect Dis J
; 23(2): 99-109, 2004 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-14872173
13.
A randomized, open-label study of the immunogenicity and reactogenicity of three lots of a combined typhoid fever/hepatitis A vaccine in healthy adults.
Clin Ther
; 26(7): 1084-91, 2004 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-15336473
14.
Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects.
Vaccine
; 26(45): 5712-21, 2008 Oct 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-18762226
15.
Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3).
Vaccine
; 24(23): 4914-26, 2006 Jun 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-16632108
16.
Dengue virus infections in the first 2 years of life and the kinetics of transplacentally transferred dengue neutralizing antibodies in thai children.
J Infect Dis
; 194(11): 1570-6, 2006 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17083042